Hims & Hers Health, Inc. (HIMS) Beats Q1 Earnings and Revenue Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.05 per share a year ago.
Hims & Hers (HIMS) Blows Out Earnings Expectations
Hims & Hers Health, Inc. reported a strong financial performance for Q1 2025, with revenue reaching $586 million, marking a 111% increase year-over-year.
Hims & Hers Health Revenue Jumps, But Outlook Disappoints
Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook missed Wall Street's expectations.
EARNINGS ALERT: HIMS
While Palantir (PLTR) trading was vastly unchanged after hours , Hims & Hers (HIMS) saw some downside action following its earnings. George Tsilis notes it has "become quite profitable over the years," attributing part of the sell-off to the telehealth company's valuation.
Can Sustained Product Demand Drive HIMS Stock Before Q1 Earnings?
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the first quarter of 2025.
Hims & Hers: Revolutionizing Healthcare
The company's vertically integrated platform enhances scalability and efficiency, controlling the entire patient experience from consultation to medication delivery. Partnerships, especially with Novo Nordisk for GLP-1 weight-loss drugs, significantly boost revenue and deepen customer relationships. Embracing AI and peptide therapies positions Hims & Hers for future growth, though regulatory compliance and reliance on third-party suppliers pose risks.
Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?
Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
Hims & Hers vs. Teladoc: Which Telehealth Stock Is the Better Buy Now?
Both HIMS and TDOC are technology-intensive healthcare companies that leverage their strengths in the digital health space to enhance their platforms. Which one is a better investment?
Hims & Hers Stock Soars on Novo Nordisk Collaboration
Every once in a while, investors come across some of the best names in a given industry, which then become subject to the best news and developments during a holding period. Today's best pick seems to be in the medical sector.
Hims & Hers stock price soars after partnership with Novo Nordisk to offer weight-loss drug Wegovy
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordisk. That partnership will see Hims & Hers offer Novo Nordisk's weight-loss drug Wegovy through its platform.
Hims & Hers Health (HIMS) Stock Jumps 23.0%: Will It Continue to Soar?
Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Hims & Hers stock pops on Novo Nordisk partnership
Hims & Hers (NYSE:HIMS) shares surged after it announced a partnership with Novo Nordisk that will allow it to offer the drugmaker's weight loss product Wegovy through its telehealth platform. Investors welcomed the collaboration, which positions Hims & Hers to participate directly in the fast-growing market for GLP-1 weight-loss drugs.
